Articles

In clinical trials, roflumilast cream demonstrated rapid and sustained improvement in the signs and symptoms of atopic dermatitis in patients 6 years of age and older.

Arcutis Biotherapeutics Seeks FDA Approval for Roflumilast in Atopic Dermatitis 

The companies will partner up to design and implement solutions that support each other's business efforts.

Cryoport, Nippon Express Establish Supply Chain Services Collaboration

In clinical trials, KarXT (xanomeline-trospium) demonstrated a combination of strong tolerability and clinically meaningful symptom reduction in adult patients with schizophrenia.

FDA to Evaluate Novel Treatment for Schizophrenia 

CDC finds administration rates for influenza antiviral medication was lower than during pre–COVID-19 pandemic flu seasons.

CDC: Lower Flu Vaccination Rates Lead to Higher Adolescent Hospitalizations in 2022-23 Season

Biden Administration invokes Defense Production Act to facilitate domestic manufacturing of essential medicines.

White House Takes Action to Address Ongoing Drug Shortage Issue

Studies explore how both the UK and EU are handling these ongoing supply chain challenges.

Beyond the United States: How Drug Shortages Are Impacting the European Continent

The approval of Ogsiveo represents an important therapeutic advance for patients with progressing desmoid tumors requiring systemic treatment.

Ogsiveo Approved by FDA for Progressing Desmoid Tumors 

Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration. 

Examination of 340B Drug Pricing Shows Program is Beneficial to Patients, Costly to Manufacturers

The designation—which ranks the fastest-growing companies in North America—is powered by AeroSafe’s 477% growth rate.

AeroSafe Global Ranked Number 280 on Deloitte’s 2023 Fast 500

AbbVie and Genmab will share commercial responsibilities in the United States and Japan for epcoritamab-bysp (Epkinly) for the treatment of adults with follicular lymphoma that is relapsed or refractory following treatment with two or more therapies.

News